Skip to main content
OpenTrials

Clinical trial condition

Hormone Refractory Prostate Cancer

Explore clinical trials studying Hormone Refractory Prostate Cancer. Study availability and eligibility vary by location and protocol.

21 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Hormone Refractory Prostate Cancer trial results

Completed

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

NCT01260688

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +9 more
Locations
  • Illinois CancerCare-Peoria Peoria, Illinois, United States
  • Central Illinois Hematology Oncology Center Springfield, Illinois, United States
  • Fort Wayne Medical Oncology and Hematology Inc - State Boulevard Fort Wayne, Indiana, United States
  • Johns Hopkins University Baltimore, Maryland, United States
View Trial Details
Completed

Study of Weekly Cabazitaxel for Advanced Prostate Cancer

NCT01518283

Conditions
Hormone Refractory Prostate Cancer
Locations
  • Complejo Hospitalario Universitario de Santiago Santiago de Compostela, A Coruña, Spain
  • Institut Català D'Oncologia L'Hospitalet (Ico) L'Hospitalet de Llobregat, Barcelona, Spain
  • Hospital de Sant Joan de Déu Manresa, Barcelona, Spain
  • Hospital Universitario Fundación Alcorcón Alcorcón, Madrid, Spain
View Trial Details
Completed

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

NCT00069745

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +9 more
Locations
  • Birmingham Hematology and Oncology Birmingham, Alabama, United States
  • Birmingham Hematology and Oncology Birmingham, Alabama, United States
  • Hematology Oncology Associates Phoenix, Arizona, United States
  • Northern AZ Hematology & Oncology Assoc. Sedona, Arizona, United States
View all 211 locations
View Trial Details
Completed

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00571675

Conditions
Disease, Genital Diseases, Genital Diseases, Male, +13 more
Locations
  • Colorado Springs, Colorado, United States
  • New Port Richey, Florida, United States
  • Ocoee, Florida, United States
  • Fishers, Indiana, United States
View all 35 locations
View Trial Details
Completed

Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy

NCT00407251

Conditions
Hormone Refractory Prostate Cancer
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • BC Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada
  • Juravinski Cancer Centre Hamilton, Ontario, Canada
  • London Health Sciences Centre London, Ontario, Canada
View Trial Details

Related conditions